Ulcerative Colitis Study

COULD I QUALIFY?

PARTICIPANTS MUST:

CURRENTLY BE EXPERIENCING SYMPTOMS SUCH AS DIARRHEA WITH OR WITHOUT BLOOD, STOOL URGENCY, OR INCONTINENCE OF STOOL.
HAVE BEEN DIAGNOSED WITH ULCERATIVE COLITIS.
BE 18 TO 75 YEARS OF AGE.
MEET ELIGIBILITY CRITERIA DURING SCREENING AT A PARTICIPATING DOCTOR’S OFFICE.

YOU DON’T NEED HEALTH INSURANCE OR REFERRALS TO PARTICIPATE. HOWEVER, ONLY THE INVESTIGATIONAL DRUG/PLACEBO WILL BE PROVIDED. OTHER DRUGS YOU ARE TAKING FOR ULCERATIVE COLITIS OR FOR OTHER CONDITIONS WILL NOT BE PAID FOR BY THE STUDY.

WHY SHOULD I PARTICIPATE?

PARTICIPANTS MAY:

TRY AN ORAL INVESTIGATIONAL DRUG TO SEE IF IT REDUCES THE SIGNS AND SYMPTOMS OF ULCERATIVE COLITIS.
BE MONITORED BY A LOCAL STUDY DOCTOR.
RECEIVE REIMBURSEMENT FOR STUDY-RELATED EXPENSES.

Get Started Now!

Don't Worry! You are not committed to participate in a study by completing this form.

By hitting "Submit" button you consent us to send you SMS updates. Frequency may vary. Message & data rates may apply. Reply STOP to opt out or HELP for more information. View our terms and privacy policy at our website

Seela Ramesh, MD

Dr. Ramesh is a board-certified Gastroenterologist with extensive expertise in Advanced and Therapeutic Endoscopy, ERCP, Endoscopic Ultrasonography (EUS), and the management of liver diseases. He completed his medical education at the Medical College of Virginia, an institution globally recognized for its excellence in Gastroenterology and Hepatology.

A highly experienced Principal Investigator, Dr. Ramesh has led numerous clinical trials across a wide range of therapeutic areas, including hepatology, inflammatory bowel disease (IBD), and metabolic liver disorders. His research contributions have helped advance innovative treatments, and he has been published in leading peer-reviewed journals. His work includes studies on hepatitis C, nonalcoholic fatty liver disease (NAFLD), and the role of cannabinoid receptors in hepatic metabolism.

Dr. Ramesh’s publications and presentations include:

Ramesh, S., & Sanyal, A. J. (2004). Hepatitis C and nonalcoholic fatty liver disease. Seminars in Liver Disease, 24(4), 399-413.
Ramesh, S., & Sanyal, A. J. (2005). Evaluation and management of non-alcoholic steatohepatitis. Journal of Hepatology, 42(1), S2-S12.
Ramesh, S., Mirashi, F., Choudhoury, J., & Sanyal, A. J. (2005). Cannabinoids block interferon-mediated suppression of hepatitis C virus replicon. AASLD, Poster Presentation.
Ramesh, S., Mirashi, F., Choudhoury, J., Gupta, S., & Sanyal, A. J. (2005). Methanandamide promotes hepatic lipogenesis by increasing SREBP-1 and SREBP-2 activity—a novel effect of cannabinoid (CB1) receptor activation. AASLD, Poster Presentation.
Qasem, A., Ramesh, S., & Naser, S. A. (2018). Role of TNF antagonists in susceptibility to mycobacterial infection in association with genetic polymorphisms in Crohn's disease. UCD Biomedical Sciences Annual Graduate Research Symposium, Poster Presentation.

Dr. Ramesh is a Clinical Assistant Professor of Medicine at the University of Central Florida and plays an active role in training medical professionals at Osceola Regional Medical Center. He is also a distinguished member of professional organizations, including the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE), the American Association for the Study of Liver Diseases (AASLD), and the Crohn’s & Colitis Foundation (CCF).

With a strong background in clinical research, protocol development, and investigational therapies, Dr. Ramesh is dedicated to advancing medical knowledge and improving patient outcomes through innovative clinical trials.